Outcomes
metabolic syndrome
METABOLIC SYNDROME, PRESSURE AREA, INSULIN RESISTANCE
All outcomes will be measured at: (1) baseline (prior to first or second chemotherapy treatment), (2) 2–6 weeks post-last chemotherapy (typically lasting 12–18 weeks, depending on prescribed regimen) and (3) 2 years post-baseline. Participants who discontinue or deviate from intervention protocols will be asked to complete all follow-up assessments. The primary outcome is visceral AT volume at the end of chemotherapy. Secondary outcomes include the remaining AT pools (thigh intermuscular and intramuscular, liver, abdominal subcutaneous), metabolic syndrome z-score, 10-year Framingham and Reynolds risk scores, cardiorespiratory fitness, chemotherapy symptoms and quality of life. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), hemoglobin A1c, lipid profile, waist circumference, fasting glucose and blood pressure are tertiary outcomes as we expect they may only change among those who are metabolically unhealthy at baseline. Exploratory or potential mechanistic/explanatory outcomes will include leptin, adiponectin, IL-6, TNF-